Ablynx
Former Ablynx exec joins Kiadis as Chief Scientific Officer
February 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, appointment, kiadis, pharma
Dutch/US firm Kiadis Pharma revealed that Dr Robert Friesen became its new Chief Science Officer (CSO) as January turned into …
Top Ten most popular articles on Pharmafile.com this week
March 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Cancer, GSK, Hemlibra, MSD, Roche, Sun Pharma, Takeda, brexit, pharma, tecentriq, top ten
As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if …
Ablynx’s vobarilizumab trial fails and sees two patient deaths in systemic lupus erythematosus
March 26, 2018Research and Development, Sales and Marketing AbbVie, Ablynx, Sanofi, Vobarilizumab, pharma, systemic lupus erythematosus
Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint …
Top Ten most popular articles on Pharmafile.com this week
February 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Alzheimer's, Apotex, AstraZeneca, Brexit Health Alliance, CDC, Duchenne Muscular Dystrophy, EMA, Italy, Sanofi, amazon, brexit, santhera, top ten
It’s the first Friday of February, and it’s time for another recap of the top ten articles most popular with …
Read Pharmafocus January/February 2018 edition online now!
January 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Ablynx, Alex Azr, Celgene, Pharmafocus, Sanofi, UK, artificial intelligence, bioverativ, brexit, juno therapeutics, multiple myeloma, serialisation
With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine …
Sanofi swoops for Ablynx in $4.8bn deal
January 29, 2018Sales and Marketing Ablynx, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi has moved quickly to tie up a deal with Ablynx for $4.8 billion, when it looked more likely that …
Novo Nordisk ups acquisition bid to €2.6 billion, Ablynx says no
January 8, 2018Sales and Marketing Ablynx, Novo Nordisk, acquisition, pharma
It has emerged that Novo Nordisk has extended a bid of €2.6 billion to buy Belgian biotech Ablynx. The new …
Ablynx posts strong data on key drug, looks set for approval
October 2, 2017Research and Development, Sales and Marketing Ablynx, biotech, drugs, pharma, pharmaceutical
In a major success for the European biotech industry, Ablynx has revealed that it had met the primary and secondary …
Sanofi makes moves with strategic $2.4 billion Ablynx nanobody deal
July 20, 2017Sales and Marketing Ablynx, Sanofi, biotech, drugs, nanobody, pharma, pharmaceutical
Sanofi is steadily recovering from missing out on Actelion to J&J by making another deal, this time with Ablynx biotech …
Ablynx secures first €1m milestone payment from Novo Nordisk
December 5, 2016Sales and Marketing Ablynx, Novo Nordisk, nanobody
Ablynx has secured €1 million from Novo Nordisk as it hits its first discovery milestone for its multi-specific nanobody construct, …
Ablynx’s RA therapy matches Roche’s Actemra in Phase IIb trial
July 7, 2016Medical Communications, Research and Development Ablynx, Actemra, Roche
Ablynx (EBR: ABLX) has presented positive data on their rheumatoid arthritis treatment candidate, ALX-0061 (vobarilizumab), in patients with rheumatoid arthritis …
Ablynx sets focus on pharma collaborations
December 14, 2015Manufacturing and Production, Research and Development Ablynx, collaboration, nanobodies, partnership
Drug development companies should prioritise strategic pharma collaborations to keep up with the next wave of immuno-oncology treatments, the chief …
Ablynx appoints Robert Zeldin as new chief medical officer
November 30, 2015Manufacturing and Production, Research and Development, Sales and Marketing Ablynx, Robert Zeldin
Ablynx has appointed Dr Robert Zeldin as chief medical officer (CMO) effective from 1 December 2015. Dr Zeldin will lead …
Ablynx and Merck begin immuno-oncology collaboration
October 15, 2015Research and Development Ablynx, Merck, immuno-oncology, nanobody, proof of concept
Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology collaboration with Merck – triggering …
Ablynx looks to GSK for new chief commercial officer
November 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, johan heylan
Belgium-based biopharma firm Ablynx has appointed Johan Heylen to be its chief commercial officer and assume responsibility for all commercial …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
